C12N 2750/14043
Viral genome or elements thereof as genetic vector
Official title: viral genome or elements thereof as genetic vector
C12N2750/14043 (Viral genome or elements thereof as genetic vector) appears on 46 US grants and 83 published applications in this corpus.
Search patents in C12N- Granted patents
- 46
- Published applications
- 83
- Assignees
- 49
- Inventors
- 172
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 2 | 0 |
| 2003 | 0 | 1 |
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 2 |
| 2007 | 1 | 1 |
| 2008 | 0 | 1 |
| 2009 | 1 | 4 |
| 2010 | 0 | 0 |
| 2011 | 1 | 1 |
| 2012 | 3 | 2 |
| 2013 | 1 | 1 |
| 2014 | 0 | 4 |
| 2015 | 1 | 2 |
| 2016 | 0 | 2 |
| 2017 | 1 | 2 |
| 2018 | 5 | 5 |
| 2019 | 2 | 3 |
| 2020 | 5 | 5 |
| 2021 | 2 | 13 |
| 2022 | 3 | 5 |
| 2023 | 7 | 6 |
| 2024 | 2 | 7 |
| 2025 | 4 | 12 |
| 2026 | 2 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency29 Sep 2026US 12,747,429 B2The Trustees of the University of Pennsylvania
- Gene therapy for retinal disease9 Jun 2026US 12,649,007 B2Oxford University Innovation Limited
- Clinical parameters by expression of factor VIII16 Dec 2025US 12,497,632 B2Sangamo Therapeutics, Inc.
- Artificial expression constructs for selectively modulating gene expression in interneurons11 Nov 2025US 12,467,064 B2Allen Institute
- Nucleic acid molecules and uses thereof for non-viral gene therapy22 Jul 2025US 12,364,774 B2Bioverativ Therapeutics Inc.
- An aav9 capsid variant for targeted gene transfer6 Aug 2026US 2026/0224742 A1Universitaetsklinikum Hamburg-Eppendorf
- Quantitative particle content assessment using hydrated state imaging and image analysis23 Jul 2026US 2026/0212690 A1Intelligent Virus Imaging Inc.
- Sod1 dual expression vectors and uses thereof19 Feb 2026US 2026/0049315 A1University of Massachusetts
- Aav-mediated expression using a synthetic promoter and enhancer18 Dec 2025US 2025/0381308 A1University of Iowa Research Foundation
- Erythroparvovirus compositions and methods for gene therapy16 Oct 2025US 2025/0320521 A1Synteny Therapeutics, Inc.
Most cited
By later US patents
- Virus vectors and methods of making and administering the same197US 7,172,893 B2The University of North Carolina at Chapel Hill · 2007
- Recombinant parvovirus vectors and method of making167US 6,491,907 B1The University of North Carolina at Chapel Hill · 2002
- Multivalent PCV2 immunogenic compositions and methods of producing such compositions30US 8,119,143 B2Boehringer Ingelheim Vetmedica GmbH · 2012
- Use of a non-mammalian DNA virus to express an exogenous gene in a mammalian cell23US 6,281,009 B1The General Hospital Corporation · 2001
- Use of a non-mammalian DNA virus to express an exogenous gene in a mammalian cell15US 6,338,962 B12002